A panel of ten site-directed mutants of Clostridium perfringens &-toxin was generated. All of the mutated proteins expressed in Escherichia coli were recognized in immunoblots by a neutralizing mAb raised against wild-type native otoxin. The cytotoxicity of the site-directed mutated toxins was assayed in vitro against MDCK cells. One mutation resulting in loss of activity in the assay was identified. This non-toxic protein was derived by substituting a proline for the histidine at residue 106 of the toxin. Immunization of mice with the non-toxic mutated c-toxin resulted in the induction of a specific antibody response and immunized mice were protected against 1000 LD,, doses of wildtype recombinant c-toxin.
INTRODUCTION
&-Toxin is produced by Clostridiurn perfringens types B and D, but not by types A, C or E (Brooks et al., 1957) . C. perfringens types B and D have a limited host range, being mainly isolated from sheep, occasionally from goats and cattle, and rarely from man (Smith & Williams, 1984) . The bacteria cause lamb dysentery and pulpy kidney disease in sheep, with mortality rates as high as loo%, and are of great economic importance wherever animals are raised intensively (Buxton & Fraser, 1977) . Neither disease is infectious, but sporadic outbreaks occur when the microbial balance of the gut is disturbed. Pulpy kidney disease is often associated with a change from a poor to a rich diet accompanied by overeating (Bullen, 1970) , causing undigested, starchrich food to enter the intestine. The nutritious, anaerobic environment produced in the intestine allows the multiplication of C. perfringens, which then produces toxins (Bullen & Scarisbrick, 1957) . The resulting high concentrations of &-toxin produce a rapidly fatal enterotoxaemia.
Several vaccines exist for the prevention of C . perfritzgens enterotoxaemia. These vaccines are based on formaldehyde-treated bacterial culture filtrates or Abbreviations: GE, glutathione S-transferase-E-toxin fusion protein; GST, glutathione S-transferase.
whole-cell cultures and confer a high degree of protection in animals (Stephen & Pietrowski, 1986) . However, the immunogenicity of the e-toxin in the preparations has been reported to be variable and inflammatory responses following vaccination to result in reduced feed consumption (Stokka et al., 1994) . Immunity to a single (conformational) epitope on the toxin has been shown to be sufficient to protect against purified &-toxin and infection with C . perfringens types B and D (Percival et al., 1990) .
The etx gene encoding &-toxin is carried on a plasmid (Canard et al., 1992) . The genes from C . perfringens type B (etxB) and type D (etxD) have been isolated and sequenced (Havard et al., 1992; Hunter et al., 1992) . Comparison of the sequences of the etxB and etxD genes revealed two nucleotide differences in the ORFs, resulting in one amino acid substitution (Havard et al., 1992) .
The cloned etxD gene encoded a protein of M, of 32981 (Hunter et al., 1992) . Recently, some amino acid sequence similarity between &-toxin and a mosquitocidal toxin from Bacillus sphaericus has been reported (Thanabalu & Porter, 1996) .
The c-toxin is expressed as an inactive prototoxin which is preceded by a putative signal peptide, resulting in the native protein being exported from C. perfringens and the recombinant protein accumulating in the periplasmic space of Escherichia coli (Bullen & Batty, 1956; Hunter et al., 1992) . The prototoxin is activated by proteases, such as trypsin, causing a shift in PI from 8.02 to 5.36 (Bhown & Habeeb, 1977; Worthington & Mulders, 1977) . The mature toxin is highly toxic with an LD,, in mice of 0.78 ng when administered intravenously (Habeeb, 1969) , making it one of the most potent bacterial toxins. The mechanism of toxicity is not known, but some amino acid residues which may be important for activity have been identified by chemical modification. One tryptophan (Sakurai & Nagahama, 1985) , one histidine (Sakurai & Nagahama, 1987a) , one tyrosine (Sakurai & Nagahama, 1987b) and three or four aspartic or glutamic acid (Sakurai & Nagahama, 1987c) residues have been shown to be essential for the lethal effect of &-toxin. Eight lysine residues have also been shown to be important in activity, but are probably involved in maintaining conformation rather than being integral to an active site (Sakurai & Nagahama, 1986) .
The purpose of this study was to identify a candidate vaccine that would protect against &-toxin intoxication, and in so doing to further understand the structurefunction relationship of the toxin. To do this, we have produced mutated &-toxins with single amino acid changes and expressed them in E. coli. We have examined the activity of these mutated proteins both in vitro and in vivo. A non-toxic mutated &-toxin was evaluated for its ability to protect mice against &-toxin challenge.
METHODS
Bacterial strains and plasmids. C. perfringens type D (NCTC 8346) was grown in TPYG broth as described previously (Percival et al., 1990) . E. coli strains invaF', JM109 and HBlOl were grown in Luria broth (LB) or on LB agar plates (Sambrook et al., 1989) , supplemented as required with 25 pg ampicillin ml-'. The plasmids used in this study are listed in Table 1 .
Preparation and manipulation of DNA. DNA was isolated from C. perfringens by the method of Marmur (1961) . Largeand small-scale plasmid isolations, restriction enzyme digests, blunt-ending and ligations were performed as described by Sambrook et al. (1989) . Restriction endonucleases, T 4 DNA ligase and sequencing-grade Taq polymerase were obtained from Boehringer Mannheim.
Production of site-directed mutations in plasmid pC10. Amino acid substitutions were selected by firstly considering the likely surface exposure of the target residue from predictions of secondary structure and hydrophobicity (DNAStar). Substitutions which might be permissible were selected from the amino acid exchange matrices devised by Bordo & Argos (1991) . Finally, the likely effects of these mutations on secondary structure were predicted using the DNASTAR program. The site-directed mutants were created under contract by Scotgen Biopharmaceuticals, using described methods (Taylor et al., 1985a, b; Nakamaye & Eckstein, 1986; Sayers et al., 1988) . A HindIII/AvrII fragment was subcloned from plasmid pClO into a M13mp19 vector as a source of singlestranded DNA for the mutagenesis reaction. Table 2 shows the oligonucleotides used in the reactions. The oligonucleotides were annealed to the single-stranded template DNA and extended using Klenow polymerase in the presence of T4 DNA ligase to generate mutant heteroduplex molecules. Nonmutant strands were removed by nicking with restriction endonuclease NciI and exonuclease I11 digestion. The mutant strands were used as a template to create double-stranded, closed circular molecules which were used to transform E. coli strain HB101. Mutants were identified by DNA sequencing or DNA hybridization. The presence of a second Hind111 site in the polylinker of the pBluescript I1 KS( + ) vector made cloning of the mutated HindIII/AvrII fragment back into plasmid pClO difficult. The strategy employed to circumvent this "The underlined codon in the wild-type sequence indicates the original sequence in etxD and in the oligonucleotide the codon it was changed to in order to produce the desired mutation.
problem is illustrated in Fig. 1 . A BamHIIEcoRI fragment of the &-toxin gene was subcloned into similarly digested vector plasmid pBR322 to produce pBR322Tox. This fragment contained unique Hind111 and AvrII sites that allowed the mutated gene fragments to be cloned into the pBR322Tox construct. The mutated etxD genes in the pBR322Tox' constructs were then recovered as EcoRIIBamHI fragments and cloned back into similarly digested pBluescript I1 KS( + ).
Subcloning of the site-directed mutated E-toxin genes into expression vectors.
The etxD gene was subcloned from plasmid pCl0 into two expression vectors, pGEX3x and pTrc99,4 to produce pHLH2 and pTEP7, respectively. Plasmids pTEP7 and pHLH2 were digested with restriction endonuclease SpeI, blunt-ended to abolish the SpeI sites and religated to produce plasmids pTEP7.1 and pHLH2.1. A HindIIl/EcoRI fragment containing the site-directed mutation was subcloned from a pC10' construct into similarly digested pHLH2.1. A BamHIIClaI fragment containing the sitedirected mutation was subcloned from a pC10' construct into similarlv digested Dlasmid oTEP7.1. These recombinant Production and purification of E-toxin. Expression of recombinant mutated and wild-type &-toxins was examined by SDS-PAGE and immunoblotting (Logan et al., 1991) .
Immunoblots were probed with a mAb, ASC12, which is specific for a neutralizing epitope on the toxin (Percival et al., 1990) .
Periplasmic fractions were prepared from E. coli strain HBlOl bearing plasmid pTEP7 and its derivatives by the method described by Titball et al. (1989) . The c-prototoxin was cleaved with bovine pancreatic trypsin attached to beaded agarose (Sigma). The trypsin-coated beads were washed and resuspended in PBS (Dulbecco's formula ; Oxoid). Aliquots of 1 ml of each periplasmic preparation were activated with 4 U trypsin for 30 min at 37 "C.
Glutathione S-transferase-&-toxin (GE) fusion protein was expressed from plasmid pHLH2 and its derivatives and purified by affinity chromatography using glutathione Sepharose 4B according to the manufacturer's instructions (Pharmacia Biotech). inactivated by addition of 10 pl 35% formaldehyde for every 100 pg toxin. After incubation at 37 "C overnight, the formaldehyde was removed by dialysis against PBS.
Activity of mutated toxins in vitro and in vivo. The e-toxin from E. coli bearing plasmid pTEP7 and its mutants was activated with trypsin and screened for cytotoxicity using MDCK cells according to the method of Payne et al. (1994) .
The significance of the difference in the activity of a mutated c-toxin compared with that of the wild-type recombinant toxin was assessed by the Student's t-test. &-Toxin from E. coli bearing plasmid pTEP7 and its mutants was purified from periplasmic extracts and activated with trypsin. Comparable levels of &-toxin purity were observed in immunoblots of all preparations. Using published data (Payne et al., 1994) , the ratio of CT,, (concentration of extract required to kill 50% of MDCK cells) to LD,, was calculated as 0,006. The CT,, of the activated periplasmic extract from E. coli containing plasmid pTEP7 was determined as 195 ng ml-', which corresponded to a calculated LD,, of 35 pg kg-l. This is low compared to purified e-toxin due to the low purity of the periplasmic preparation. Groups of six female BALB/c mice (Charles River Laboratories) were then challenged intravenously with 100 pl wild-type and mutated c-toxin periplasmic extracts diluted in PBS at a dose (350 pg kg-l) equivalent to 10 times the calculated LD,, of the periplasmic extract produced from E. coli containing pTEP7. The animals were closely observed during this acute toxicity test and time to death was noted. The test was strictly limited to a 24 h period and was performed with the approval of the on-site animal ethics committee. Immune response to mutated toxins. Groups of 30 mice were immunized intraperitoneally with 0.27 nmol each of &-toxoid, purified GE fusion protein expressed from plasmid pHLH2, purified GE-H106P fusion protein or E-H106P periplasmic extract in a 1 : 1 emulsion with incomplete Freund's adjuvant. Aliquots of the GE fusion protein were frozen at -70 "C until just prior to use to ensure that the fusion did not break down to yield active toxin (see Results). Two control groups were included, namely, mice immunized with 0.27 nmol glutathione S-transferase (GST) (Sigma) in incomplete Freund's adjuvant and unimmunized mice. Mice were given booster doses of antigen on days 21 and 35. Ten mice per group, except for the E-HlOGP-immunized mice, were bled on day 48 of the schedule and the sera titrated by a modified ELISA procedure in which recombinant wild-type &-toxin and native &-toxin was coated to the solid phase and the test serum serially diluted in duplicate on the plate. A horseradish-peroxidase-conjugated IP: 54.70.40.11
On: Thu, 10 Jan 2019 13:40:08 C. perfringens &-toxin mutants anti-mouse (Fc-specific ; Sigma) immunoglobulin antibody was used to detect bound antibody and plates were developed by the addition of ABTS substrate (Sigma). Titres of specific antibody are presented as the final sample dilution that gave an optical density at 414 nm of >0*1 after subtraction of the non-specific binding given by pooled serum samples from agematched untreated control animals. On day 54 the mice were challenged in groups of six with 10 to 1000 LD,, doses of activated recombinant wild-type e-toxin administered intravenously. The mice were observed for 24 h and times to death noted. Animals surviving for 24 h after toxin administration without toxic symptoms were deemed protected.
RESULTS

Expression of mutated &-toxin and GE fusion proteins in E. coli and their proteolytic cleavage with trypsin
Mutated &-toxins were produced with amino acid substitutions at three positions. The histidine-106 residue was changed to a serine, proline or an alanine. Similarly, the histidine-149 residue was changed to a serine, proline or alanine. The tryptophan-190 residue was changed to a tyrosine, phenylalanine, leucine or lysine.
Genes encoding each mutation in etxD were subcloned into each of two constructs based on vector plasmids pGEX3x and pTrc99A, designated pHLH2 and pTEP7, respectively. Expression of the mutated genes from pTEP7 constructs resulted in high levels of e-prototoxin. These proteins were designated E. For example, the designation E-HlO6P indicates a mutated &-toxin with the histidine residue at position 106 being mutated to a proline. Mutant genes in the pHLH2 constructs resulted in the &-toxin being expressed as a fusion protein with GST. Such GST-&-toxin fusion proteins were designated GE, for example, the designation GE-HlOGP indicates a mutated GST-&-toxin fusion protein with the same mutation described above.
In immunoblots of whole-cell lysates of the panel of mutated &-toxins or GE fusion proteins expressed in E. coli (data not shown), each of the mutants, when probed with mAb A5C12, was revealed as a protein of a similar size to that of full-length &-toxin or GE fusion protein, with the exception of the mutated toxins E-W19OK and GE-W19OK which appeared to be degraded, as only low molecular mass bands were seen in the immunoblots. The GST fusion proteins were recognized as 57 kDa proteins in immunoblots (Fig. 2a) , whilst the mutated toxins expressed from plasmids based on pTEP7 were recognized as bands of approximately 33 kDa in immunoblots (Fig. 2b) . With the exception of the E-H149P mutant toxin, the &-toxin signal sequence resulted in the mutated toxins being exported to the periplasmic space of E. coli (Fig. 2b) . Although there was a band of the correct size in immunoblots prepared from whole cells of E. coli expressing the E-H149P mutant toxin, there was only a very weak band in the corresponding periplasmic preparation (Fig. 2b, lane 3) , indicating that export, and not expression, was the cause of low levels of this mutated toxin in the periplasm.
Trypsin treatment of the periplasmic preparations resulted in cleavage of the e-prototoxin to produce the mature &-toxin. This was seen in immunoblots as the appearance of two bands of lower molecular mass (Fig.  2b) . In some trypsin-treated samples a faint band corresponding to the prototoxin was visible, for example Fig. 2b , lane 10. However, previous studies (data not shown) had shown that treatment of the recombinant toxins with trypsin for 30 min resulted in the most consistent activation of the &-toxin. Heterogeneity of Etoxin preparations has been reported previously and is thought to be due to the presence of partially and fully proteolytically cleaved forms of the toxin (Worthington et al., 1973) . The multiple bands we observed probably correspond to these partially and fully digested forms. Extending trypsin treatment of the recombinant &-toxin preparations to 2 h (data not shown) resulted in a reduction in toxin activity in the in vitro cytotoxicity assay. Examination of the same 2 h samples in immunoblots showed that the lower band predominated (data not shown), and probably reflected tryptic digestion of all available sites in the e-toxin molecule. None of the bands reacting in immunoblots were due to crossreactive epitopes in the E . coli periplasm as there was no recognition of any components of the periplasmic preparations of E. coli bearing plasmid pTrc99A (data not shown).
Activity of mutated &-toxins in cytotoxicity assay: identification of a non-toxic mutant toxin
The mutated toxins were treated with trypsin and assayed for cytotoxicity against MDCK cells (Table 3) . Three mutated toxin preparations were not toxic to MDCK cells (E-WlSOK, E-W149P and E-H106P). Of these, mutated toxin E-W19OK had been shown in immunoblots to be degraded and mutated toxin E-H149P was not exported into the periplasmic space. The mutation in toxin E-H149A resulted in an e-toxin which was significantly less active in the cytotoxicity assay against MDCK cells than the wild-type recombinant toxin (P<O*O2). The other mutations did not result in significant differences in cytotoxicity activity when compared to the wild-type recombinant toxin control.
The cytotoxicity of three mutated toxins, E-WlSOY, E-W190L and E-H106S, was compared on days l , 5 and 44 to check the stability of the toxins. The mutated toxins appeared to be stable at 4 "C over this time with no decrease in their cytotoxic activity (data not shown).
Activity of selected mutated toxins in mice: the mutant toxin E-H106P is non-toxic in vivo
The GE fusion protein expressed from plasmid pHLH2 was non-toxic in mice, but was unstable and spontaneously degraded to give active toxin upon storage at 4 "C (data not shown).
The toxicities of mutant toxins E-H106P, E-H149A, E-W190Y and E-HlO6S were determined in groups of six On: Thu, 10 Jan 2019 13:40:08 P. C. F. OYSTON a n d OTHERS Fig. 2 . lmmunoblots of the mutated &-toxin produced by site-directed mutagenesis expressed in E. coli, probed with the neutralizing mAb A5C12. The molecular mass of the expressed proteins is shown in kDa. (a) Mutated toxins produced as fusions with GST based on the vector pHLH2 following purification by affinity chromatography on a glutathione Sepharose 4B column. Lanes: 1, GE-W190Y; 2, GE-Wl90L; 3, GE-Hl49P; 4, GE-HlOGA; 5, GE-Hl06S; 6, GE-Wl90K; 7, GE-Wl90F; 8, GE-Hl49A; 9, GE-Hl49S; 10, GE-H106P. (b) Periplasmic preparations of the mutated toxins expressed from the P , , of pTrc99A, before and after activation with trypsin.
Lanes: 1, E-W190Y; 2, E-W190L; 3, E-H149P;
4, E-HI06A; 5, E-HIO6S; 6, E-Wl90K; 7, E-W19OF; 8, E-Hl49A; 9, E-Hl49S; 10, E-H106P. mice (Table 4) . Intravenous administration of 10 LD,, doses of recombinant toxin expressed from plasmid pTEP7 resulted in the death of mice within 2.48 f 0.078 min. Similar mean times to death were recorded when either mutant toxin E-W19OY or E-H106S was tested. The E-H149A preparation was less toxic in mice. Mice receiving the mutated toxin E-H106P or a periplasmic preparation from E. coli strain HBlOl survived for 24 h without showing any signs of an intoxication. Therefore, these results in uiuo mirrored the results in the cytotoxicity assay by confirming that the E-H106P protein was not toxic and that the E-H149A preparation showed reduced toxicity.
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Immunization with GE and GE-HlOGP fusion proteins induces a specific antibody response
The induction of a specific immune response against Etoxin was determined by measuring the antibody titres in sera from immunized mice. On day 48 of the immunization schedule, the mean IgG titres (in parentheses) against purified native e-toxin were recorded for mice immunized with GE (1:69000), &-toxoid (1 : 52 000), GE-HlO6P (1 : 32000) or GST (undetectable).
Protection of immunized mice against challenge with etoxin
Mice immunized with &-toxoid, GE, GE-H106P and E-H106P were all protected against an intravenous challenge with 100 LD,, doses of &-toxin (Table 5 ) . When the challenge dose was increased to 1000 LD,, doses of Etoxin per mouse, all of the e-toxoid-immunized mice, and those immunized with the E-HlO6P preparation, survived with no ill-effects. There was one death in each of the GE-HlO6P-and GE-immunized groups of six mice before the experiment was terminated at 24 h after challenge. Unimmunized mice and mice immunized with GST were not protected against c-toxin intoxication.
DISCUSSION
&-Toxin is produced by C. perfringens types B and D as a relatively inactive prototoxin of 311 amino acids with a molecular mass of 32700 (Worthington & Mulders, 1977; Hunter et a/., 1992) . Proteolytic cleavage results in the production of the mature toxin (Worthington & Mulders, 1977; Hunter et al., 1992) . Although exposure to the toxin results in rapidly fatal disease in sheep and goats, the mechanism of action of the toxin is not known. Although non-toxic, the GE fusion protein encoded by plasmid pHLH2 was not suitable as a vaccine candidate as it was unstable and spontaneously degraded to produce active etoxin. We, therefore, made site-directed mutations with the intention of producing a stable and non-toxic mutated &-toxin which could be considered as a vaccine candidate.
A panel of ten site-directed mutations in &-toxin was produced with amino acid substitutions at three positions. Chemical modification experiments had previously indicated the importance of certain amino acid residues for the lethality of c-toxin (Sakurai & Nagahama, 1985 . The histidine residue appeared to be integral to the active site of &-toxin whilst the tyrosine and tryptophan residues were necessary for the binding site of the toxin. Of the two histidine residues in the mature &-toxin protein, histidine-106 was predicted to be located midway along a region of P-sheet in a weakly hydrophobic environment whereas histidine-149 was predicted to be located close to a turn region in a hydrophilic environment. Residues found most frequently (70% similarity of environment) in place of histidine have been reported to be serine, alanine or proline (Bordo & Argos, 1991) . The chemical modification of histidine residues (Sakurai & Nagahama, 1987a) would lead to cleavage of the imidazole sidechain with a resultant loss of functionality or disturbance of the secondary structure at this position. Our finding that substitution with alanine or serine at position 106 or 149 did not abolish lethal activity indicates that the imidazole side-chain does not play a role in activity of the &-toxin. However, the mutation of residue 149 to an alanine resulted in a significant decrease in activity of the recombinant toxin both in vitro and in vivo, which may result from a conformational change of the protein affecting its activity. From the comparison of hydropathy and secondary structure plots using DNASTAR software by the methods of Garnier et al. (1978) and Chou & Fasman (1978) , the mutation of either histidine residue to a serine should have caused least disruption to the toxin structure. The substitution of proline at these positions would be expected to be the most likely substitution to cause a local conformational change. Although all the histidine substitutions resulted in stable mutated toxins being expressed, the H149P mutation resulted in a protein which was not exported into the periplasm of E. coli. The substitution may have disrupted the protein structure, resulting in a conformation that could not be efficiently exported into the periplasmic space. This supports the suggestion that this histidine residue is important for the correct conformation of the active toxin as indicated by the H149A mutation. The mutation in &-toxin of H106P resulted in a protein that was non-toxic in mice suggesting that a structural motif in this region is essential for biological activity. It is possible that this mutation caused a gross conformational change in the protein. However, our findings that the mutated protein was stable and exported into the periplasmic space and that it induced protective immunity suggest that protective epitopes within the gross structure of the protein were unaffected by the change.
The single tryptophan residue in c-toxin, at position 190, was predicted to be located close to a hydrophilic turn. Tyrosine, phenylalanine, leucine or lysine were the most frequently observed substitutions for tryptophan in a 70 % similarity environment (Bordo & Argos, 1991) . Of these mutations, substitution with tyrosine or phenylalanine would retain aromatic side-groups. The finding that the W190L mutation yielded a cytotoxic &-toxin indicates that the aromatic side-chain plays no role in activity. When predicting the effect of the mutations on secondary structure, the substitutions of tryptophan with tyrosine or phenylalanine were predicted to be conservative substitutions whilst mutation to lysine or leucine should have disrupted the structure, and hence activity, more markedly. Of these mutations, W190K would be expected to cause the greatest change in structure at this position and this may explain the instability of this mutant, which was degraded upon expression.
The formaldehyde-treated &-toxoid induced protective immunity against challenge with 1000 LD,, doses of toxin. The GE and GE-H106P preparations induced some protection against 1000 LD,, doses and complete protection against 100 LD,, doses. High IgG titres against &-toxin were measured in mice immunized with c-toxoid, GE or GE-H106P 6 d prior to challenge with Etoxin. The similarity of these antibody titres indicates that most of the B-cell epitopes were conserved between the native e-toxin and the wild-type or mutated recombinant toxins fused with GST. Of these candidate vaccines, the GE fusion protein was not considered to be suitable as it degraded on storage to yield active toxin. In contrast, the E-HlO6P toxin was shown to be non-toxic, indicating that the GE-HlO6P preparation could not yield active toxin if degradation of the fusion protein occurred. In addition, the approach of using a GST fusion has the advantage of providing the means of purification by affinity chromatography.
In summary, chemical modification studies have previously identified certain amino acid residues as playing an important role in the activity of c-toxin. The production of a panel of site-directed mutants of c-toxin has allowed the contribution of these residues to be evaluated. One non-toxic mutated toxin was identified and was evaluated for its ability to protect mice against €-toxin intoxication. However, further work is required to identify other mutations which also result in abolition of toxicity of &-toxin. A single codon change would carry the risk of reversion to full activity, which would be unacceptable for a vaccine formulation. Therefore, at least one further mutation must be introduced into the toxin to reduce this risk. As a veterinary vaccine for sheep, lambs and cattle, the non-toxic site-directed mutated toxin would have several advantages over the currently available commercial vaccine. The recombinant vaccine would be well-defined and standardized and thus the immunogenicity of the vaccine would be more uniform than the current vaccines, which are produced by formaldehyde treatment of bacterial culture filtrates or cell cultures. In addition, this vaccine should be easier and cheaper to produce as it would bypass the need to grow large volumes of a dangerous pathogen, relying instead on the culture of a laboratory strain of E. coli. Finally, as it can be produced in a highly purified form, the mutated &-toxin could be combined in the future with other purified vaccine proteins to produce a multivalent vaccine formulation to protect against a range of animal diseases.
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